Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination

Mathieu Rouanne,Laurence Zitvogel,Aurélien Marabelle

DOI: https://doi.org/10.1158/2159-8290.CD-20-0786

Abstract:In this issue of Cancer Discovery, Diab and colleagues demonstrate in a phase I trial enrolling 38 patients diagnosed with advanced solid tumors that combining the pegylated IL2 bempegaldesleukin with an anti-PD-1 mAb is safe, with an overall response rate of 59.5%. This compelling clinical activity is supported by the potent immune proliferation and activation of circulating T and natural killer cells with a >4-fold increase in the CD8/regulatory T-cell ratio in tumors, independent of baseline PD-L1 expression.See related article by Diab et al., p. 1158.